<SEC-DOCUMENT>0001558370-24-010321.txt : 20240730
<SEC-HEADER>0001558370-24-010321.hdr.sgml : 20240730
<ACCEPTANCE-DATETIME>20240730083018
ACCESSION NUMBER:		0001558370-24-010321
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240730
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240730
DATE AS OF CHANGE:		20240730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		241154499

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nrbo-20240730x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/29/2024 9:46:51 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: 4693f05c-6c1d-4098-b114-4f7a5b5ee5a0 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:nrbo="http://www.neurobopharma.com/20240730" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityCentralIndexKey" id="Tc_uhxl8EbN0k6NT1KnyE5qWw_1_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:AmendmentFlag" id="Tc_wlyJkOIwvkaqymLjdfqDwQ_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nrbo-20240730.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-30</xbrli:startDate><xbrli:endDate>2024-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:52.71pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_aa879659_64a8_4977_8f35_cdfd712b74e0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:DocumentType" id="Narr_rv1YcC-d6kGegorQMf6sxQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_7-Li-WW1cEmXqe_nIGDxQQ"><b style="font-weight:bold;">July 30, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nrbo-20240730x8k001.jpg" alt="Graphic" style="display:inline-block;height:52.71pt;width:191pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityRegistrantName" id="Narr_WLW_a55aW06KOpRrS0_tVA"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_13452a04_9467_4692_bd89_690379252b8f"></a><a id="Tc__IEMFgBd406HqPctivWAZQ_2_0"></a><a id="Tc_lKFnDA1LcUWW6nRvTBK1_g_2_2"></a><a id="Tc_Z6TGcp_HTEyUnI_5__NnSA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_hoUXI-pbfECzd14W-07A_A_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityFileNumber" id="Tc_BNrU8yoNg02XBITAkVTAAQ_1_2"><b style="font-weight:bold;">001-37809</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityTaxIdentificationNumber" id="Tc_99JGtVBgaEmVgdAfQRH5tw_1_4"><b style="font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_a03c4018_f776_4435_ac00_d380f9b56282"></a><a id="Tc_ImV5e9WT5EeUKTXrMRht6g_1_0"></a><a id="Tc_lxAIZmsZhEGnH87X180ChA_2_0"></a><a id="Tc_bcrnWczu6kW7A7ncMSFjKQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityAddressAddressLine1" id="Narr_jn0I3ZAXsEG7QRUj1kJEXg"><b style="font-size:9pt;font-weight:bold;">545 Concord Avenue</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityAddressAddressLine2" id="Narr_5jRmrrss5UaZiPz_zAszwQ"><b style="font-size:9pt;font-weight:bold;">Suite 210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityAddressCityOrTown" id="Narr_MhXsQgrLZkqg8awj_7AD0Q"><b style="font-size:9pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_gUW-kFe1I0qd-l3h6hNgCw"><b style="font-size:9pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:EntityAddressPostalZipCode" id="Tc_cOBANCAqIUq0MTve8x25Nw_1_2"><b style="font-size:9pt;font-weight:bold;">02138</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:CityAreaCode" id="Narr_FPxCyA4aU02Nuk2S-JBNKw"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:LocalPhoneNumber" id="Narr_w31osO2VAU-2MT-i893gVA"><b style="font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_e51ff3d8_d6f6_44c9_b338_8f565e4a1604"></a><a id="Tc_IME1m5uo6UOtOV6PpgLFCQ_1_1"></a><a id="Tc_iuoJpeiMYkewQm_Vrc1RgQ_2_1"></a><a id="Tc_vKMmG-pHEUqXmq8n_WWvFA_3_1"></a><a id="Tc_YJSKh-fKqEG_CEdgsyJEdg_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_5h6g4hEA9EC3GgPQ1eQgrg_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_euM64HtP9EyB6Kh9W2bJLQ_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_aLBdzX085EiuQVmpOEBzaA_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_WNh98_UGXk2TZC23-WBChA_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_0c311cdb_c736_4079_9d07_0deae2867d84"></a><a id="Tc_jXz8SF_h2Uae7yT_7f-p8A_1_0"></a><a id="Tc_-pYX301gekKGwcP_cClaYQ_1_2"></a><a id="Tc_dTTqrYRf-Eiul6pG_osLNA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Symbol(s)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:39.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:Security12bTitle" id="Tc_TR9HsZHeG0mxFpz9l_VFoA_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" name="dei:TradingSymbol" id="Tc_5MQyyiiefk2bp2widweLHg_2_2">NRBO</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_CqAHn2lW7EqvdBcjPNFxcg_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_HfwUFXq1BkGkeHQlZkvKHg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8b59797b_fc93_4805_8527_08b11b2f8eb1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 7.01</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span><b style="font-weight:bold;">Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On July 30, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. (&#8220;MTHERA&#8221;) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the &#8220;Report&#8221;) and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk171944681"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company&#8217;s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_887af5ec_0648_4e74_bc9d_8dd00c411bd6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01.</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit<br/>Number</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:85.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;Description</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20240730xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#cceeff;">Press Release dated July 30, 2024.</span></a></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_04573877_a4d3_466a_8633_6e4326b497ee"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;">Date: July 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hyung Heon Kim</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hyung Heon Kim</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nrbo-20240730xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 7/29/2024 09:46:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;">Exhibit 99.1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nrbo-20240730xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:57.27pt;width:171.48pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CAMBRIDGE, Mass., July 30, 2024</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;--&#160;NeuroBo Pharmaceuticals, Inc.</b><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;(Nasdaq: NRBO), </font><font style="font-family:'Calibri','Helvetica','sans-serif';">a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, today </font><font style="font-family:'Calibri','Helvetica','sans-serif';">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. (MTHERA) with the &#160;rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> and South Korea</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, for the future commercialization of NB-01. Financial terms of the agreement were not disclosed. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;Finalizing this agreement for NB-01 is an important milestone for NeuroBo, reflecting our stated commitment to out-license our legacy assets in order to focus on the continued clinical development of DA-1726 and DA-1241,&#8221; stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. &#8220;MTHERA has extensive experience in manufacturing, quality control and clinical development of natural medicines and botanical drugs, making the company an ideal partner to continue the development of NB-01.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:14pt;padding-top:14pt;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;Based on the positive Phase 2 efficacy results for NB-01 for diabetic neuropathy, we intend to develop it as a potential treatment for peripheral diabetes,&#8221; stated Dr. Mi Won Sohn, Chief Executive Officer of MTHERA. &#8220;Utilizing our SyMthomics platform technology, we can clearly identify the mechanism of action and active ingredients of NB-01 to assist in predicting its clinical efficacy as an innovative treatment, with the intent of advancing NB-01 into the next phase of clinical development. </font><font style="font-family:'Calibri','Helvetica','sans-serif';">We are grateful to NeuroBo for the opportunity to further advance NB-01, and to potentially bring this promising therapy to patients in need.&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About MThera Pharma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">MThera Pharma Co., Ltd., headquartered in Seoul, South Korea, is a biopharmaceutical company developing first-in-class botanical drug products</font><font style="font-size:12pt;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';">using novel, multi-component/multi-target-driven disease-modifying therapies to address diverse etiology and treat chronic incurable diseases such as Parkinson&#39;s disease, dementia and inflammatory bowel disease. MThera&#8217;s platform technology, SyMthomics, consists of its MThera-CODA system (AI based in silico system), a cutting-edge multi-omics integration technology, as well as systems biology and bioinformatics. MThera&#8217;s standardization technology and advanced CMC technology for raw materials, drug substances and drug products are designed to meet the U.S. Food and Drug Administration requirements for therapeutic consistency. For more information, please visit </font><font style="font-family:'Calibri','Helvetica','sans-serif';">www.mtherapharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.4pt;">About&#160;NeuroBo Pharmaceuticals</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">For more information, please visit <font style="color:#0563c1;">www.neurobopharma.com</font>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &quot;believes&quot;, &quot;expects&quot;, &quot;anticipates&quot;, &quot;may&quot;, &quot;will&quot;, &quot;should&quot;, &quot;seeks&quot;, &quot;approximately&quot;, &quot;intends&quot;, &quot;projects&quot;, &quot;plans&quot;, &quot;estimates&quot; or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with NeuroBo&#39;s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo&#39;s current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo&#39;s contract manufacturers, clinical study partners and others involved in the development of NeuroBo&#39;s current and future product candidates; potential negative interactions between NeuroBo&#39;s product candidates and any other products with which they are combined for treatment; NeuroBo&#39;s ability to initiate and complete clinical trials on a timely basis; NeuroBo&#8217;s ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo&#39;s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo&#39;s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo&#8217;s filings with the Securities and Exchange Commission, including NeuroBo&#8217;s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contacts:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals</b>&#160;<br>Marhsall H. Woodworth&#160;<br>Chief Financial Officer <br>+1-857-299-1033</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#0563c1;">marshall.woodworth@neurobopharma.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Rx Communications Group</b>&#160;<br>Michael Miller&#160;<br>+1 917-633-6086<br><font style="color:#0563c1;">mmiller@rxir.com</font><font style="color:#2683c6;">&#160;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nrbo-20240730x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20240730x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !K 6@# 2(  A$! Q$!_\0
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M<DGX]D+ _>(.<>G-?I>33E4PL>62TW_X)_/?$L(X;-)\]-J+M9WZ6Z>1MO\
M#'7C]VWC?_=F4_UID/P[\564GFVUM+%(.CQ3!3^!!K!>253]]_S-5WGE QYK
MX_WC7O.,VM6K'#AL12^))_>>BQV_C&: 6^L>'XM=M]NW_2E7S0/:0'(/OR:Z
M7X9^$[_0_'6CZQX=BOO#>K1SK&(;LB:WD#<,C$'.Q@2#WYR.0*\.>XE'_+5_
M^^C73Z!X?>RMX=<UN]GTVPC8/ D3D3W!!!_=CL.GS>PKCKT'*FU=:]+;GV.!
MQ?OQ=F[=6_U/T:B^$/A>$^+'M]-%I+XIB\K5'@E9?-&QE^49PI^=SD $EB37
MYP?'7X:Q_";XEZIX<M[EKJTAV2P2/C>8W4, V.XS@^N,\5[S9?M\ZS:Z8\-Q
MX:M;J[7(CG^T,@([;EP<GUP1[8KSGPSJGBS]HKQI/!?Z!9^(IKEPTUWY1MQ9
MKQC]ZOW5 & #DG'?FOF\LH8O+YSJXCX+6W^X^YQ6)PV-C"%#XO0XCX*?">]^
M,/CZQT.W5TLPWFWUT@_X]X!]YO3)Z#U)';-?JCI>F6^DZ=:V%I"L%I;1K##$
MHP$10 H'T %<5\(?@UH?P;T!].T:#,T\GFW-U*=TDK>F>RJ. /ZDD^AU\[FN
M8O'U?=^%;?YGT&!POU:G[WQ,83DUYY\>/AU>_%CX5ZUX7L+B&TO+T0[)K@$H
MNR9)#G )Z(?QQ7H9P32!L']:\:E.=&I&I#=.YUUJ4*].5*:TE^1YY\"/AW>_
M"CX5:+X7O[B&[O+(3>9-;@[&WS/(,9 /1Q^.:]%'%-W9R.])OQGT'>G4J2K5
M)5)[O5^HJ-*%"G&E#9:(<0/RKQ?]HW]G:P^.WAZ(1M'8>([,G['J#+QM)YCD
MQR4/4=2",CJ0?:2PH!]*TP^(JX:I&K2=I+8G$X:EBJ4J5573W."^"7@2\^&/
MPOT+PS?3PW=WI\;H\MOG8Q+LPQD ]&K2^(?PYT'XI>&KG0_$%D+RREY!SB2)
MA]UT;JK#U^H.02#U1P10 ,TG7J2K.M?WF[W7?<4<-2C15"UXI6U/D&U_9N^+
MOP?NW3X;>.Q<:1(<"PU%5*H,YSL8,F>F67!/L*GU+X2_M$?$A?[-\2>-K31M
M(<CSAIP6-G7H1F)59N"?E+;3W%?6VX>O6D#8)Y_ UZCS>L]90BY=W%7_ .'/
M(_L6BER1G-1[*3L>5_!7]GCPW\$=/?\ LR-[W6KA0+K5KH!I9<<X'78N?X1Z
M#)) ->DZKI5IK>FW5A?6Z75G<QF*6&095T8$,I]B"15QF'J*4L!CGOBO)JUZ
ME6I[6I*\CV:6&I4*?LJ<;1['R)?_ +)_CCX5^(9]6^$7B]].M9F);3+TY4 ]
MB&!20#G!8;AQSGFK=]\-_P!H[QY#_9>N^,K#0]*E&)Y=.1$E9<C(#(N[IGH0
M#R#P:^L332ZC)S7K?VO7DO?C%M=7%7^\\?\ L:A%^Y*45V3=M?(^/O'O[!RW
M7A[PSI_A34[:"YL7GEU*]U(,9;R201 $;0<!?+;"YXSU))-?7Z1_NPI],9%*
MI&.><TNX9Z_A7#B,;7Q48PK2NHWM\]3OPN7X?"2E*C&W-:Z]#PSX=? /5O!O
M[0'B[QY<:A:3Z?K$<B0VT8?S4+/&PW9&.B'H?2O=0>2*:K8SSFD# $FL*U>=
M=J51W>WW&^'P]/#)QIJW7[R*>VCNX'AF19(W4JR,,@@]017R[XX_8RN-,\2R
M^(_A=XCG\(:@YWM9J["'<6R0C Y"GCY""OT'%?5&<FDSAOZ5MAL96PCO3=K]
M.C]498O!4,8K5EMUZ_)GRB?"O[4EU;K9R>*-)@4G:UVD4&\#U_U?\A6Y\*/V
M/+3P]XDC\5>.=8E\:>(D(>,W+,\*/_>.XDR$<8W<#K@G!'TGO&.M)D8^E=<\
MUKN#A!1@GORJS?S.&&3X>,U.HY3MMS.Z0H7& ./85\L_&O\ 9=\:>._C _C?
MPQXEM-!G6".*%]TB3QLJ;&(90<9!(X[&OJ9'!XSS1N'K7'A<55PDW4H[M6=]
M=&=^,P5+&P5*LM%KIHSY!_X9O^/G_17'_P# RX_PJ.3]F;X[W.U)OB[.J \F
M*^N5/Z 9_.OL/>,#FD!&[_&NW^UJZZ1_\!7^1YO]BX?O+_P)GS'X%_8@T73]
M>76_&FN7OC2_1E=8[HD0EAWDR6:3H."0/4'/'TO#;I;PI%$BQQ(,*BC  ]*G
MQ294GIUKCQ.,K8N7-6E?MV^[8]+#8&AA%:C!+OW^_<X'XL?!SP[\9?#K:7XA
MM"Y0EK>[A.V:W;&,HW\P>#W' KY^TW]GWXW_  CE-KX$\=1ZCHS'"VNH $(!
MZ)(&"YR?N$9QSVKZ_P #Z4;@>];8?,*^'A[+24>S5U_P/D88G+*&)G[76,NZ
M=F?(>I_ ?XZ?%EQ9^./'4.F:,#\]MIRJ-X(Y!6,*'''1V.,\5[W\(_@MX=^"
M^@?V;H5J3)+AKF\FYFG8#&6;T]%' R?4D^A>G)I"P)ZXHQ&8UJ\/9.T8]DK+
M_@DX?+*&'G[764N[=V24445YQ[ 4444 0O#O&" 5Z8/->(_%3]E#PUX_EEO]
M.)T#56Y:2W4&*4_[2= ?=<>^:]THKIH8FMAI<]*5F>=C,OPV/I^SQ,%)'YW>
M,_V5_'OA5F>+3EUB ' EL6WDCU*GD5YIJ7@?Q#IC[;K0]0MSG;^\M7 SZ9QB
MOU6";N_T'I39+2.4 2(KCT89KZ6CQ)B(*TXI_@?#5."<)S\]&HUY;GYEZ7X+
M_P"$92*[U/3I]4U5P&MM(AC9\'LTN >G]VE3X4_$CXE:J)?^$>U"5W.T--"8
MHHE[ ;L8 _SU)K]+ET^WC;>L$8<?Q;!G\ZG"9'7'TH?$55ZQAKW.^CPO3II)
MU';LE^I\8?#K]@Z]NI8[GQEJJVD ()L=/(>1QZ-(1A?P!_"OK/P=X"T/P!HL
M6E:!IL.G648'RQ#YF/JS')8GU))KH<4M>%BLPQ&,_C2NNW0^JPN7X?!K]U'7
MOU&D>E+D^E+17FGHD9ZUYW\>_%>I^"/A/KNMZ1.MMJ5JL1AE>-7"%ID4\'@\
M,17HF,&O./VAO"^H>,_A!X@T72[9KN^N5B$<*G!;$R,>?H"?PKHPZC[>'/M=
M')BN?V$W3WLS!UW4O&GPR.D:GJ'BRT\3:==:C:Z?/87&GI;3$3S+$&A>-N74
MN&*D$%5;H>:Z3XW>+[_P/\-[[6].G2VNX+BT7S) I54>ZBC?.>/NLU3:%\%O
M"F@:E!J$6GRW5[ 0T,M_>377DG'5!*[!#UY'/)YJK\>/"U[XQ^&.HZ18VWVR
MYGN;-A!QAD2[B=^O&-JM^5=*E3G7AS;7UT25O1:'#[.O3H3L[.VBNV[^ID?&
M;XQZ9X<^%^NZGX?\2:3)KEM;;[98[F*9M^0/N9.>M>M1DE%)],FO'?C7\&]*
MUCX3^(;'P]X:L#K4UMMMO(MHT<ON'0XX/!KUJ:9[:PD=8GE>-"1&GWF(&<#W
M[5E45+V4?9[W>_RM^IK0==59.LM.5;?,\:^*/Q6UWPWXU+Z.(CX:\-1PW/B5
MC%O=HYV"A4XR&CCW3'!^[M]<'VJWN8[J".:-@\;@,K+R"#W%>(^$/@EK&I^&
MM0N]<\4ZSI6H^)'EO=7TJTCLI+=&E7:81YUO(Y58PB8+$?*2,9Q7:_!G2M:\
M/>"H]"UT223Z//)8V]W(5)NK9#^XE.._EE5/NAJZT:7):#U6G]?,SPLJ_M&Z
MJTEJOZ]#%UF?Q7XD^*>MZ-I'BK_A'=/TW3+&Z"BPBN#))-)=*Q)?I@0+^=7/
MAAXNUK4_$OBOPQK5S;:K<: ]NBZM:P^2+@2H6VLF2%=<<X./F' JEJ_PDL?&
M'Q1\1ZGKVFM/I\NE6%M:3B9D.]9+HR@%""" \?/OQ5OX*>&-1\!:=J'A>_L4
M$&G3_P"B:M#&JB_@8?(T@&/WJCY6..2 V3DU<Y4W3<5:Z2Z+3;6^[,Z<*JK*
M3NDV^KUWTMT,WXS_ !#\0>!/&/A$Z9&MUHGV:_OM9M5C#2O;Q-;)OC.,[D\\
MO@?> (]*P_C;\<]0TF#3(?!$L%T=UG>:AJ&T2106L\R)$!D$%I=^1Z*I/I7H
MNN^'[S4/BKX7U-8?,T^UTK4[:>0XPKR2691<>_E/_P!\GUKB?'WP3L]#^%>I
MZ)X/TTFXO=7MKYX]P)(%W$[#)Q\J(N%7LJ@>]:X>5"]-5%K_ ,'KZ$8B&*?M
M73=EIZZ+IZGM:/E5]2*\1\=?%W6/#_Q">:U6,>#M FM;37G9 6+W.0I5L<"'
M,+MSR)3Z<^OZO>SZ=H]W<VUK)?7,,+.EM$0'F< E4&>,DC'XUXYX9^ &I7?@
M:ZL]:\9:Y;7&NB:ZUBQM([(P--/S*H,EN[X&=@RY. ,8X YL/[-.4JGH=.*]
MM)1A2O??MLCW 29 (P/6O);/Q!XL^*.O:Y'X?UB/POH&CWLFFB[^QK<7%Y<1
M\2D"0[4C5LKT)8JQR.*ZCX16NN:;X$L-+\1[Y-4TPMI[W+G/VI(VV).#_MJ%
M;GG)-<EI%EXA^$VO^(H8-$O/$/AK5=0DU.VDLG1KBUEF)::)T)&4WY92,XW8
M.<4J<5&4E%IM;7V?WA5G*4:;DFHO>V_SL>@^#M/U_3-->W\0ZI;:Q=)*1%=V
M]M]G+Q8&/,7)&_.[.W QCC->2:CXSUW4_BQXVT0_$*R\'Z?I#V:6L-Q:V[M)
MYENLCG,A!.&/ZUZWX4UC5=:L)[G5-';1',V(+>299)#%@89]O"L3GY<GH*\D
ME\,S:5\7/'>JZKX$F\2V.J/9-9W,<$,H CME1Q\Y!'S#'X5MAK*4W.U[:;;W
M7?0RQ?-R4O9WM?SVL][:GK?@A+M= @>[\01>)G=F9=1AA2-'7L $)4XYYKGO
M!_BS4-9^*/C[1+F19+#2#8?9%" %?-@+OD]\G!KH?!ETMQHJ"/0Y_#\4;%$L
M9T1"HZY 0X R3^M<+<6>M?#[XH>)]?M]%NM=T?Q!#:LWV J9K::%2A!0D95E
M(.1G!S6$(QDZD7NUIMW7Z'3.;A&G..R>OI9G2Z#XDO[_ .*/B[19G4V&G6>G
MS0)M (:4W&_)QSGREKE/C_>>,/"/A+6O%.A>*O[/M["W5UTUM.BE5VW $F1N
M><_I6Q\-=&UN;Q;XL\5ZU9_V7_;'V6WL]/<JTL4$"R;6D()&YFE<XSP,"K/Q
MZ\.:AXL^$OB32-*MVNM0N[<)#"" 6(=3C\JU@X4\1#16]V^S72YE.,JN%G>]
M];;I[NVQL>!]"\0:/%.VN>)3XB,P0Q$V,=MY0YR/E/S9XZ^E4+SQ)?Q?&+3?
M#R2JNFS:'<WKQ[!GS4G@13GT"R,,5VMNICAB4C!"C-</>:!?2?&W2];6 G38
MM!NK-YLC E:XMV5<>ZHQ_"N5RYYR<O\ +\CIY'3IQC"_3JQ_Q6\<7/@;0;1M
M.M8[S6-3O8=-L(9F*QM/(2 7(YVJ 6..H7'>J.C^%/B!9ZA9W=UXXM=2A:53
M=V,FDI'&4)^81NK;@1_"6+>^:G^+W@N_\8Z)I\ND21KK&CZA!JMG'/Q'+)&3
M^[<]@RLPSV.#3=+\?>(]3N[*T_X0>_LY?,5+N6[GB6"%=P#LK@GS,#. !SQG
M%;PO[+W+/O>WZ_H8U/XW[V_2UK_C;]3T!G"YR<5XAI?Q?U>Z^*,<TC1_\('?
MZA-H%G(8P&^VQ*"92W='=9H@,]4'K7I'Q&N-:B\%:L/#D!GUR:+R;/! $<CG
M:)"3V3.\^RUYEJ?[-]TOPY7P[9>.M?*6<*-9V\D5B(5N(R'C<E;82?ZQ58G?
MN///-/#*DHMU7OI_P?R(Q;KN25%;:]OD>YE^"17 _"#Q3J/BRP\22ZC*LKV6
MO7UA"50+B&*4J@.,9.!UKIO">H:CJ?A?3;G5[$Z;JLMNAN;4G(CE*C<H/<9S
M@^E>5_#W4=?^'G_"365UX/U:]6[UZ^OH;BT\LH\4LI9#RP/2LX4^:,XK=>9M
M4JN,X2=[:]ST[QYK5]X;\%ZWJFG6;:C?V=G-<06@!/G2*A94P.>3@8%>>_#/
M4/$7BK[#JUO\1=.UZV;:]]IJ:=&@B##E4*L'1@<@;\].:]'O=2U)O#)O]/TO
MS=3:!98].NYA$2Y /ELX! (Z9YY%>0:MH%[XO\4Z#>:1X*NO"FMVNHP3WFL2
M&.)?LZOF:(E&_?!URN#QSNXQSK02<)1=EYZ/\_T,L3?VD)*[\M5^7ZGOH[44
M*, 9HK@/6%HHHH **** &A<4%<TZB@!"N:0)BG44 %%%% !1110 W;[TUHMW
M?CZ5)12 ;LS36BW=3^E24460$;19'!Q^%'E9 &:DHIBLB/RN1S3?(QG#8)]*
MFHI6&1^7G/\ A2&'+9S^E2T46 C$1!SFAHLGMCTQ4E%%@(VBW9YZ^U'E=\^]
M2446 B$ 7H31Y/RXSTZ5+118")H<KC=CW%'DBI:*=A6&>7SUXIHAP"-V?K4M
M% R(PY/4TICW8Y_2I**5D W9[TGEC.?Z4^BF!&8L]^O6CR1G_P"M4E%)I/<"
M+R1QDY/TI?*YZ_A4E% $8BP,9XI/(&3SP>U2T4 1^5[T>5CI_*I**8!1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nrbo-20240730xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20240730xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !S 5<# 2(  A$! Q$!_\0
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M^#KJG4BX+[S[K_:'_:PTKX/WMOI.DK%K'B)9T-W9G(6&'J=S=F(Z=?4UZO\
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MS'9:/JEOXYU":2]@*"32K>YMS$ZD_P#+1U/?T_.NFECIX# 1EBU::6B[]O\
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nrbo-20240730.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/29/2024 9:46:56 PM-->
<!--Modified on: 7/29/2024 9:46:56 PM-->
<xsd:schema targetNamespace="http://www.neurobopharma.com/20240730" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:nrbo="http://www.neurobopharma.com/20240730" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20240730_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20240730_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nrbo-20240730_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/29/2024 9:46:56 PM-->
<!--Modified on: 7/29/2024 9:46:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nrbo-20240730_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/29/2024 9:46:56 PM-->
<!--Modified on: 7/29/2024 9:46:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20240730.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638578864166356709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638578864166356709" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638578864166356709" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638578864166356709" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638578864166356709" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638578864166356709" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638578864166356709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638578864166356709" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638578864166366722" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638578864166366722" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638578864166366722" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638578864166366722" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638578864166366722" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638578864166366722" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638578864166366722" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638578864166366722" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638578864166366722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638578864166366722" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638578864166376714" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638578864166376714" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638578864166376714" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638578864166376714" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638578864166376714" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638578864166376714" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638578864166376714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638578864166376714" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139967882977120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROBO PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">545 Concord Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRBO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( ,A#_EB7BKL<P
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,A#_E@'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R$/^6(A@
MP?7N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ R$/^6)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #(0_Y8J3\K9W$$  !9
M$0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ R$/^6)^@&_"Q @  X@P   T              ( !M P
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #(0_Y8EXJ[',     3 @  "P
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52P4&      D "0 ^ @  %!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nrbo-20240730x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nrbo-20240730.xsd</File>
    <File>nrbo-20240730_lab.xml</File>
    <File>nrbo-20240730_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="nrbo-20240730x8k.htm">nrbo-20240730x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nrbo-20240730x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nrbo-20240730x8k.htm": {
   "nsprefix": "nrbo",
   "nsuri": "http://www.neurobopharma.com/20240730",
   "dts": {
    "schema": {
     "local": [
      "nrbo-20240730.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nrbo-20240730_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrbo-20240730_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nrbo-20240730x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrbo-20240730x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrbo-20240730x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-24-010321-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-010321-xbrl.zip
M4$L#!!0    ( ,A#_EA,SKP>> ,  %\,   1    ;G)B;RTR,#(T,#<S,"YX
M<V2U5EUOVC 4?9^T_^#E/1^$E@H$K=9UDRK1;>HZJ6^3<0Q82^S,=@;]][LV
M<2 A"73:G@@^Q\?GWNM[D^G--DO1;RH5$WSF#8+(0Y03D3"^FGF%\K$BC'DW
MUV_?3-_Y_O/MXQPE@A09Y1H12;&F"=HPO49/(L\Q1P]42I:FZ%:R9$41&D3!
M51 % ^3[I<8M5K!'<&3%XF!0(1]*/<$GZ"J,QV$<Q1=H/+D832Y'Z.M#17P
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M^VVT?P.=:<!M,"=?OO+,XR_+MD-5%]T\V/NQ/W97A)W*]1]02P,$%     @
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MG73>;X4UENUV/T\1JZJ"VS(Q=;XHJ;I$%$DW3,W25<OB>5,2!,,J;N(%:;Q
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M>?@1B$6"GF8+IO!$V/PJ^$Y02D7W5'%'V?VWIZI=WZ3[L8Z;\,+-T1F3 GT
M!__SPU\;'X&+S^[4Q5J-L^J9#OJU 2:0&U'(W6"SZHAEM(\GP32SW0CK3%74
M9Y-ZO7.)/1[SI=.0>B[1I$SZH+))XZG%0X)FQE6%.5,15R!6( 0?MK[D6:T
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MDZ;WN/L-#D"PI[D:/#,'ZNG@XAK1UJHUMT>H:++DU$0*A,Y:C+3XNPP&0;K
MB1 F&TO4QH#A7M835>6&G#+9+_)$CN0<WA-S&TKF[6A>E,C:RI<;DDO/"/>7
M*6M57@+;;G.43MF3$UH$@E.INW8Y64^[\IKR:;_-0*G?'K%<ZHQ@R>1 -9%<
MH;.6NJT?WZ:]T@@<^,WP2@/P%''"<I]Q+VPT(*G/8/X9S$XUPQHCETM@ZFFE
MZT?\R.!6^R^WWT '</EA519+UIR;#SS]^XZC!%I&!5+;VZW-G?M/$I..#EXS
M<XG3MWT#>,]?[;&99%2<;.=6&L#=J^!XU/+W@L(GM[.M_KWD7LZ;3M,OGB?G
M7&GS(KQI> ^$DS19H87YO=^BA?4?84E@)JLY@JK*; F!GJ%.>Z$4.$"XTX/6
MJ?.]"SW3+J#' Y9Y1+!4$TGQE9OQFD%O4HQ522:6]NBIN4^=U-]OOV*"\5I9
M"- 7 IVZF0:-"8T5M%'<?;]=SDI[WOH-P*-Z3>VJ(]O';I3$]+.TI_P/[YIG
M!\3!)55[2X8BA-6]W UP/YM3*2IY(/^%)C."! &M0'.NBE!WL3VV,OM<!"NV
MU"09H;G^=E/+D2$XE0+\V2<28%$!HXW'2E6U^JJ44V2N(8!7KV8[7Q4$&6W>
M&$W8N>TFY]7O@+G0YJ4HWC65ULH]^LJ&0O=J%J> Z1ZF[PR( "5QQMUOW5 Y
MS,\VL9* \362:"E;T?FJDRHS'@ZA]];TO%RAGR ]+4_V5?YQW-IR?*L".\@:
M!$N2V$ZUN2$&]]CR?JZ/&-"[S5HE5$&4(_KS,B9IE49H7.UDMJ::WA30F%K_
MW&XQ2/@GUHE0A04?>>GGBE2M-M792Z@5FG+M/UR1WSBN-5E@[O8B=V5+8PNW
M C6:_Z;Y.P(.E)Y-\9XFK.JFMM-2RG.'#B11V*$&UA+S"RP60VJV@[-E:+PC
MG[?&K$!9%BJOS772Y6>C9&9GGZ>W,T51UT+UPP\/CWZU>F*+M/J]XH-<HE28
M#UH@46CM@J$J:VNO!HOC-]\;-ZF;4_/J#UZEO-(^'X)RHF817CHS*O2HR '8
M/[;?"E,SBQYM<:X3(\><5')*;!>E1<% ,LXW@792?)J0P&C6KJLC2Q.3]K20
MO*M@=.5-UE^_:4N%$7W3QC](:*PJ8_W*/=141^(#%3;$U/LE5'J\]7)^[I<(
M?0DVN:N7[T./5VRXW1N;$_=)MQ/"^E<E:DY)E?L"DL)5R(!LD,AZBG:?/H6Q
M]!)4\E;[]'GYB\."1LUT_V]:N5Z\Z18] A2TIRGB.>9 A(O.3)OR:LFYB*\V
MWXW2J<7B\J!)=OE;U::TC<X,4X,6MI:)PB%793/([)]Q"B'L1$NYMGLG]!FS
M):0OE ]57+F[H!7;N<8Y>;XLT;_[\'?LZA ?W%:8SKZ(D.)Z>CR22W2F7I4.
M!86Q38\VE'O_4&X1K012IX@2EE@#!5Z8V_B$)7U[+Y0!1:0,]',S@+1*#Q:
M!L4CA1;65OH";Q5G=/,?$I'>_X0\.^FS1CU:2]#JLO+_N19\RT#C-HD#_'+_
MVU\FMNIP*O7)\:I,Q4QN\].\O+1/NJQ>G]6>:)Q>?<?A6(Y0V;#^GLQ-^T?X
M,N5*/ Y @U9?-6!!/=]+KIR)N03>'CE/.]X37NR=&>J0C#\V4.H@^0=(TH&A
M%I'CAO#7DSR(Y[]M.6<^9D7^K--F8*K]$T/#2LB4&:KUJU0E?;?E).I$FCJV
M@WEJAEO2H!Y>K^BV*=?3EF*99A-\;8 #@"!6ZZ 0A/[X,Y1YZ6X>]:1V4_OT
M$31/N2N%:$D?)L@M]&#-O*:$ZZ**RT1,S\0*!^@^V-5\P%)\9"OK5%P55UQZ
MY'IM>O&@36O GMDOB1K]-+#23'SU"!]HK1<XC_?F2I[<M+HKZDFKSV#:C<_!
M3?OAC7_21Q\/(/_%GR>UA77/2;YW\1NZQ*>(HV83 UQ6B0L_K@++E8']5EOU
M_2T"+3.//7AKGDA-G@F%\;=V$/M3-LL1L*Q2O5.MU3<JW?5=;Z]+<]"Y6FD8
MO,(34.,EF&G+&._E>HS*AP*346"+I)X;XJ1@@2Q1;'\C,W,F+?(1_K-Z7K/A
M<_[8ZL'UEJ1PLY;M[%7=>V*]P9O34CT+P4O-XPLI,G.I8=B%",_ (>DA-R8[
M'I0>%!7+(J4[3H,"FD[Q31T5U/@"XRR=^8MB_B:GK60822;,R?<)>;]*2[/R
M\ B!_&-T>:29G>(N%NQU5KVK0C5Y@9'4"P;3[&<L],%UGIO[7ZZXB#$1*_4-
ML9^U*KX73Y2TTRY!C=M.81\'+#Y7I:EHXR[>HW;.^+UDM=BJO6U=D>C#0[B6
M=&#7N*;G:#I3(=@\+>4_P3$:+;+Y_>W7OL^1(6W"])!,P1]0ODR8I)L]L]+'
MLOT.PNS>!H7\>>G</^^?/<17=-+BEB<$P;@C/")KTI:.@MT:KFS/)?K./AA=
M?JQ'7];^6\AK7 UOM<4G:442V@E\='::<HC@U;+K(N37E]]N/B%!U1K.A#Y$
MW3YO3G[[&WXO:I[A/A%HCJ+# )3#M@MB]6UD$R(]ET>K,KQ[]=CE^=/\*K5G
MGR0,#FQ$^O+J$;?K43$7MR%,![83:/5[Y;)SY-\KBR)T: R3TYWN;[J02(?S
MLBHD!]<7+<_N^HYYTA;+'>9U9+CH_D"E8'& ]:2X.LM<O<A<E^)1? ] 9-J2
MU]" _&E&LT'25=X31%)X/91AUTX(.][XN]'<5KINM]#<HXONK6?@^)XU]SU?
M#T\O)E1M7] TY-+^<F#>X_#\2@C>1T@A,//UB^:VF\V&$B5Y+?( EA45IT*'
M2GT!KUPX,&QM)*.\_\DBRCAIN#XL0NFYE-F55ZVMJ)/<<!73Q_:+AKWCH^KJ
MU1"*7C8EXX;F=>-UWB?/:&7$%P.?Y22EH><WH(6&;4A^M#U+W0HU7UG+NP7.
MT8.!WRZCVJL:\N<4O)3F0,\BN3=&3Y[&SU('_K#71C;JSLS@^\[5L9?+9O/B
MFS4U.MD$EXFCA=-'\CY\P '$!O<V???ZGW3J5X#[O#AL4.SJ=1X*,XJCCL;M
M47J_(YV%V0UX[C/SYI;A.2;^]/Y7LHME0'UV*;%<7@Y8GS6**#3^Z"B0DMQO
M"/FFN;_XF;O'HK'#'1SWCZ(3F1A3/%*@S7; IO*3N-R% ZWU.#GUME$Y3/C)
MN&.8'AP=LJZL?SP\B:4)OI4']>DV>^[$O([X"#BL(CM[(OF)1,F%L4WLL'U$
MY:KQX(9E"BM[X@6?Z=SPFCHG?M\\U!<0F8D$F[>@\CG@4F#$YY5]>E>F#RQ=
M7@V]/[[K?M3RR[HO.4U2&:35"TQP%R-RA\&^LEX,_3I]AU"C'=QQ_9HZ+]EV
M*Q*847PKNRP&2T<<92;6GV:\S[=<'&*,CO#DY=GX8#:GC:TVC5EI.AN70@RG
MQ/G9W8"[T=%]+<?:KZR!BYO!WT/)&+O0]Y'Z^>LCU'2Z)<,U[1GM(0YD)A31
M;]+*".+?KOI59?<$1>:7HNSUFJ</];/+1CPCMZ=RHK>$9!\J]_N$[=F9(^YT
M!Y8+W*/GY+>*L;KPO#@XV/444:I)8JC)>#9" *^-4'$=$_;;]C JCU\3# 8N
MG9]P <W_L2/L&LO<9CQ*5N;G1[V)?A!>PX683+IV4C]_M@M&C!LBF6,[8.76
M:(W)^@/GA:L%=[>)']%/M@S+231)[GN-ZP,G3OQ$M-LDO,XQ8J-3"T09R@K'
M#K2B:BK6<H3X"BYY&H'$E3_L4)U]"O>VDU?+H>1 _Y9X^G] .I9U^]KR;=<8
M30S";W@5.78L/E9']S[--C,OZ0Q#62U[^36E]70ZU+[T)+^>X6$7ZZ\F:@NK
MA[\^D=\Y&S,#XZA"+.!I<P%9K!\#X)7&__+ECO.9N(^A*NG\#)\\_TQ:B2P;
M[!F]TOA*6V?)P1'*$&@)<"[X]:TB&EVE);7"RPI[#=')BC5CY<[,P0$B>*)$
M<K#I(@P6I+W/.;8CXP0;E,7O%G]*^+6<%W3[:NOC>+NV!A,^#\ N?&(3W32N
M_S^Q61Q5LHY+KS9C,V+]&2,#01?K63Q=O/ZA]2(,E-&PU"GXMRM'"+S@5_K7
M>_,GVEOQ.S?&NT6$SH^O#F:2^%QP@$JC5]H%5_AB?-ZIJ>>%I\T'*),T0\(W
MCRE=8@WNOSWK/C*:4*.]MCL/M-A#E^D\^G2'B8>;_]\ 4$L#!!0    ( ,A#
M_EB\H@>E;P\  !PW   8    ;G)B;RTR,#(T,#<S,'AE>#DY9#$N:'1M[5MM
M<]LV$OXK.&?:QE.2DFS'+Y*;.<=.DUSCQ&,[T^M'D(0DU"3! J!E]=??LP!)
M4;+E)!<U;6>:F402"2YV%[O/OC''_PK#E\64%XE(V>OK\[<L54F5B\*R1 MN
M<74F[91=J[+D!3L76LLL8R^T3">"L4$_VH\&.\^B?A@^/P:MT_HA50S906_G
MJ+?3W]EC_:/AWOYP[XA=G+.G'ZY/M]WJL_>GU[]<O/3;7GQX\?;-*=L*>[V?
M=T][O;/K,W]C+^H/V+7FA9%6JH)GO=[+=UML:VIM.>SU9K-9--N-E)[TKB][
M4YMG>[U,*2.BU*9;SX_I"OX5/'U^G O+63+EV@C[P]:'ZQ_#0ZRPTF;B^7&O
M^?1K8Y7.GQ^G\I89.\_$#ULYUQ-9A%:5P]U^:4=XLH?;*VONPIE,[70XZ/>_
M&94\364Q"3,QML/!(#K87US3<C)=7%1>N*$6&;?R5A#U1_;.\6,J'(7=??SN
M[(D'R^:QL2IL..:YS.;#[TYY)F,MOPN^>RVR6V%EPO'=0*^A$5J.OQNYY4;^
M+L 6B&:R$,TN@VAP-++BSH:@,@&?='7DV1IZ;;R\F\I86G9T% V.>^5782.!
MG0K=X8/1W\&._T*ZD/F$&9W\L%7H6(5DC/V#W?Z=N#LZ2J&O0?1K.=EB/(,]
MO-*\G,IDJV$[E:;,^'PH"\="G*GD9E0S\NP@VCE8*/Y@$.T=UC91/F 722:X
M'L;*3D>K)O+0R?]1FFML#XQ8E0^)X\>42:S$2ZS,/+%892ENOA.55B\4NX!'
MY3P1%;&4&792%*H"H!CV\B[)*@.IV%L)\D:PDXD6PL&+@Y7SZZG0O*; QDJS
M=R]"^/MQ+W[^B!%=RQS4WXD9NU0Y+Z &=X74<4\3.P]I(N;)S42#RW3X9.S^
MK,A-!#9S"K7OUCI_ABNWTL!3,FGGPZE,4U%@PV^?'.[T=T?'/7IZ4Z)_S'U^
MK8R5X_G'M1%_B2J6C>;TY/S%Y9NS5R\#=LZ-B0+VGRJ;L]U^P,@[W<%O<+MO
MGPSV^Z,P])]K+#9@;XHD<EM_P;DWFSU]QTW*?QNR=Y<OWF\'K#G3+R*-N(63
M)&Y#8SE";RR5%<FT4)F:S%FB<H3G.3PHJ8P+O\Q.!;,4-N%5.2>,86K,$JY3
MJ2@00D$R80 YP8TP&V$R8%:E?+XAB6L423="S:G#P.B!?Z0'Y#*B!:>L!B?>
M@%/ 2JUN)8'E"D2=*ECL6YM&[.GY]>N7ER?;'LB(O#]^%QH--%%#&8&:/PMD
M1@[YL'W)93&N,JB?Q\0P*\@R2VZG\XAAPP4KB$V9FAGF=R.RB2K2*K%,"QR=
M3J:0)6VM ]M(9]&R@'0D0,#BRK)"68B92\K-K H89R7LI[!83*)!^-T5&J#@
M^/Y0N(>N+/*ZS9B)8_A*55#;3PI:V9#M-8H>5[;2@EPB%SJ!)/+WUOS=D43L
M1UD@XR4A$?%R0W?LDM)G A1(9_"/)$,VB0/?+#8_&);^'VS^(R-5)^_\>P:N
M+X3SPYV=_HB,!39$6&"GTG2L9)&OT.6"R;Q4VG+<P2;"6%4(O\:'G0 N.\Y$
M8AT&51J,N5J)+%5Z:(![PR_"!I!H428F/)DSQ$H!6(%3*IT*32L=V#=0#U0
MW4ITH" 5MR)398,Y9R?AX&!GWWD??=_9&P1.Q,&HX>3UO )KKP5H_B3S@%T
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MOWWQ^]/[>/_TKS^[?_WES>I;)=./]:I[_K]]N?]']OQ_4$L! A0#%     @
MR$/^6$S.O!YX P  7PP  !$              ( !     &YR8F\M,C R-# W
M,S N>'-D4$L! A0#%     @ R$/^6*JC4G*%!0  ACX  !4
M ( !IP,  &YR8F\M,C R-# W,S!?;&%B+GAM;%!+ 0(4 Q0    ( ,A#_EAD
M%K;3A@0  (TG   5              "  5\)  !N<F)O+3(P,C0P-S,P7W!R
M92YX;6Q02P$"% ,4    " #(0_Y8<4PC0#D8   AN   %
M@ $8#@  ;G)B;RTR,#(T,#<S,'@X:RYH=&U02P$"% ,4    " #(0_Y8*V 1
M2WTN  !X+P  %P              @ &#)@  ;G)B;RTR,#(T,#<S,'@X:S P
M,2YJ<&=02P$"% ,4    " #(0_Y8O*('I6\/   <-P  &
M@ $U50  ;G)B;RTR,#(T,#<S,'AE>#DY9#$N:'1M4$L%!@     &  8 D@$
' -ID      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>nrbo-20240730x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nrbo-20240730.xsd" xlink:type="simple"/>
    <context id="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_uhxl8EbN0k6NT1KnyE5qWw_1_1">0001638287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_wlyJkOIwvkaqymLjdfqDwQ_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_rv1YcC-d6kGegorQMf6sxQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_7-Li-WW1cEmXqe_nIGDxQQ">2024-07-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_WLW_a55aW06KOpRrS0_tVA">NEUROBO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_hoUXI-pbfECzd14W-07A_A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_BNrU8yoNg02XBITAkVTAAQ_1_2">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_99JGtVBgaEmVgdAfQRH5tw_1_4">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_jn0I3ZAXsEG7QRUj1kJEXg">545 Concord Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_5jRmrrss5UaZiPz_zAszwQ">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_MhXsQgrLZkqg8awj_7AD0Q">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_gUW-kFe1I0qd-l3h6hNgCw">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_cOBANCAqIUq0MTve8x25Nw_1_2">02138</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_FPxCyA4aU02Nuk2S-JBNKw">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_w31osO2VAU-2MT-i893gVA">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_5h6g4hEA9EC3GgPQ1eQgrg_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_euM64HtP9EyB6Kh9W2bJLQ_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_aLBdzX085EiuQVmpOEBzaA_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_WNh98_UGXk2TZC23-WBChA_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_TR9HsZHeG0mxFpz9l_VFoA_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_5MQyyiiefk2bp2widweLHg_2_2">NRBO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Tc_CqAHn2lW7EqvdBcjPNFxcg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_30_2024_To_7_30_2024_j_O_jdmed0-1iFTpWkE9CQ"
      id="Narr_HfwUFXq1BkGkeHQlZkvKHg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
